Tag:
RGN-259
Latest Headlines
Latest Headlines
RegeneRx sets sights on dry-eye treatment
RegeneRx, a Rockville, MD-based biopharmaceutical company, has decided to put most of its resources for the near term into its dry eye treatment, RGN-259, the company announced in a news release.
RegeneRx refocuses development program
RegeneRx said that based on encouraging "compassionate use" data showing RGN-259's potential healing effects in patients with non-healing corneal ulcers, the company will close its current Phase II
